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Abstract
Background: Anti-cancer immune responses may contribute to the control of tumors after conventional
chemotherapy, and different observations have indicated that chemotherapeutic agents can induce immune
responses resulting in cancer cell death and immune-stimulatory side effects. Increasing experimental and clinical
evidence highlight the importance of natural killer (NK) cells in immune responses toward multiple myeloma (MM),
and combination therapies able to enhance the activity of NK cells against MM are showing promise in treating this
hematologic cancer. The epigenetic readers of acetylated histones bromodomain and extra-terminal (BET) proteins
are critical regulators of gene expression. In cancer, they can upregulate transcription of key oncogenes such as
cMYC, IRF4, and BCL-2. In addition, the activity of these proteins can regulate the expression of osteoclastogenic
cytokines during cancer progression. Here, we investigated the effect of BET bromodomain protein inhibition, on
the expression of NK cell-activating ligands in MM cells.
Methods: Five MM cell lines [SKO-007(J3), U266, RPMI-8226, ARP-1, JJN3] and CD138+ MM cells isolated from MM
patients were used to investigate the activity of BET bromodomain inhibitors (BETi) (JQ1 and I-BET151) and of the
selective BRD4-degrader proteolysis targeting chimera (PROTAC) (ARV-825), on the expression and function of
several NK cell-activating ligands (NKG2DLs and DNAM-1Ls), using flow cytometry, real-time PCR, transient
transfections, and degranulation assays.
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Results: Our results indicate that inhibition of BET proteins via small molecule inhibitors or their degradation via a
hetero-bifunctional PROTAC probe can enhance the expression of MICA, a ligand of the NKG2D receptor, in human
MM cell lines and primary malignant plasma cells, rendering myeloma cells more efficient to activate NK cell
degranulation. Noteworthy, similar results were obtained using selective CBP/EP300 bromodomain inhibition.
Mechanistically, we found that BETi-mediated inhibition of cMYC correlates with the upregulation of miR-125b-5p
and the downregulation of the cMYC/miR-125b-5p target gene IRF4, a transcriptional repressor of MICA.
Conclusions: These findings provide new insights on the immuno-mediated antitumor activities of BETi and further
elucidate the molecular mechanisms that regulate NK cell-activating ligand expression in MM.
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Background
The epigenetic readers of acetylated histones, bromodo-
main and extra-terminal (BET) proteins, employ tandem
bromodomains to recognize specific acetylated lysine resi-
dues in N-terminal tails of histone proteins. Members of
the BET family including BRD2, BRD3, BRD4, and BRDT
modulate gene expression, by recruiting transcriptional fac-
tors and chromatin-regulating enzymes to specific genomic
locations [1]. Among the four known members of the BET
proteins, BRD4 has been studied and characterized more in
detail in recent years as a transcriptional coactivator of
many cellular genes and in various regulatory pathways
connected to different pathologies. Through its ability to re-
cruit the elongation factor P-TEFb (a heterodimer of CDK9
and cyclin T) to the transcription start sites, it can induce
the phosphorylation of the RNA polymerase II, activating
the elongation of transcription [1, 2].
Under normal conditions, BET family proteins perform
transcription regulatory functions, while in cancer, they can
upregulate aberrant transcription of key oncogenes such as
cMYC, BCL-2, and IRF4. Interestingly, many of these onco-
genic drivers are regulated by a particular class of regulatory
regions called super enhancers, formed by binding of high
levels of specific transcriptional factors and coactivators
(e.g., BRD4 and mediator) [3]. It has been proposed that
genes regulated by super enhancers are particularly sensitive
to BET inhibition [2], as demonstrated by genomewide ana-
lyses performed in MM1.S multiple myeloma (MM) cells
and subsequently in Ly1 lymphoma cells [4]. In this context,
oncogenes regulated by super enhancers can represent
“druggable” targets for BET inhibitor-directed therapies.
The recent discovery (2010) of potent and highly spe-
cific small molecule inhibitors for the BET family of bro-
modomains (BETi), such as the triazolodiazepine-based
JQ1 and the quinolone-based BET protein inhibitor I-
BET151 among others, has shown that these molecules
are able to bind to the KAc binding pocket of the bro-
modomains and disrupt their interactions with histones,
thereby displacing BET proteins and their associated
transcriptional regulatory complexes from chromatin
(reviewed in [5]).
In this context, compelling preclinical evidence of BETi-
mediated antitumor efficacy in refractory hematological
malignancies has been provided, particularly in acute
leukemia, myeloma, and some lymphomas, at drug levels
that are achievable in vivo and with sufficient data to sug-
gest acceptable off-target effects. Accordingly, these studies
have led to the introduction of a number of early-phase,
dose-escalation safety studies in the clinical arena, and sev-
eral phase I trials using different BET inhibitor compounds
covering most hematologic malignancies (including MM)
are currently underway [6, 7] (https://clinicaltrials.gov/ct2/
results?term=bromodomain+inhibitor&Search=Search).
MM is an incurable hematologic cancer characterized by
clonal expansion of cancerous plasma cells in the bone
marrow (BM) and its development is supported by a
progressive impairment of immunosurveillance, mainly
attributable to T lymphocyte and natural killer (NK) cell
alterations [8]. Its development and progression is driven
by transcriptional regulatory events that affect the differen-
tiation of B cells to plasma cells, which subsequently sup-
port the growth of dysfunctional plasma cells. Deregulated
activity of different transcription factors (TFs) has been im-
plicated in MM development, including cMYC, MAF, NF-
κB, and IRF4. The aberrant activity of these TFs in MM is
demonstrated by the presence of translocation events that
fuse them to active enhancers driving dysregulated expres-
sion. In this context, IRF4, a critical regulator of the normal
adaptive immune response, plays a major role in MM pro-
gression; indeed, interference with IRF4 expression is lethal
for these cells, irrespective of their genetic etiology, making
IRF4 an “Achilles’ heel” that may be exploited therapeutic-
ally [9, 10]. Downstream targets of IRF4 include regulators
of cell cycle progression, survival, and normal plasma cell
function [9]. Interestingly, while oncogenic translocations
of IRF4 have been found, myeloma and other lymphoid
malignancies are more frequently dependent on dysfunc-
tional transcriptional networks downstream of a genetically
normal IRF4 locus [9].
NK cells are cytotoxic innate immune effectors involved
in anti-cancer immune response, due to their ability to ex-
pand during the early stages of this disease and to recognize
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and lyse cancer cells. A number of evidence in myeloma
patients strongly support the antitumor potential of NK
cells in response to immunomodulatory drugs or following
allogeneic stem cell transplantation [11–14]. In this regard,
evidence is accumulating that the engagement of NKG2D
and DNAM-1/CD226 activating receptors is critical for NK
cell-mediated killing of MM, which express NKG2D and
DNAM-1/CD226 ligands [8, 14–17]. However, BM and per-
ipheral NK cells become unable to efficiently counteract MM
as the disease progresses. Indeed, MM can inhibit NK cell
functions directly, by producing immune suppressive factors
and/or reducing their susceptibility to NK cell recognition. In
addition, MM cells can undergo decreased surface expression
of NK cell-activating ligands (e.g., NKG2DLs) [18], while ex-
pressing (together other cell population in the BM) ligands of
inhibitory receptors such as the ligand of PD-1 (PD-L1) [19,
20], likely providing a mechanism of tumor escape.
Thus, improving NK cell responsiveness may be a
promising therapeutic approach to treat MM; in particu-
lar, the modulation of the balance between activating and
inhibitory NK cell signals and the sensitization of cancer
cells to NK cell-mediated cytotoxicity may significantly
contribute to enhance anti-myeloma immune responses.
We have previously defined several regulatory mecha-
nisms of NK cell-activating ligand gene expression in MM
cells [21] and recently demonstrated that immunomodula-
tory drugs (IMiDs—e.g., lenalidomide or pomalidomide)
can upregulate cell surface expression of the activating li-
gands MICA and PVR/CD155 on MM, enhancing NK cell
recognition and killing [13]. A prominent role in these
regulatory mechanisms is played by the TFs IKZF1/3 and
IRF4, able to repress the basal transcription of these genes.
Thus, we identified IKZF1/3 and IRF4 as “druggable” tran-
scriptional repressors of NK cell-activating ligand expres-
sion in MM, underlying the concept that targeting specific
TFs critical for MM development and progression can
cooperate at the same time with the activation of killer
lymphocytes able to fight this cancer.
In this work, we describe the ability of BETi to upreg-
ulate the NKG2DL MICA (cell surface, messenger RNA
(mRNA) expression and promoter activity) in MM cells,
with little or no effects on the expression of other
NKG2DL (e.g., MICB) and the DNAM-1L PVR/CD155.
Moreover, exposure to BETi renders myeloma cells more
efficient to activate NK cell degranulation.
Mechanistically, we found that BETi-mediated inhibition
of cMYC expression correlates with the downregulation of
its direct transcriptional target IRF4 and with the upregula-
tion of the microRNA-125b-5p (miR-125b-5p), a modula-
tor of IRF4 expression [22, 23]. Accordingly, lentiviral-
mediated overexpression of miR-125b-5p inhibits IRF4 and
increases MICA expression in MM cells, extending the
possible immunoregulatory role of miR-125b-5p as promis-
ing anti-MM effector.
Finally, selective CREB-binding protein/E1A interacting
protein of 300 kDa (CBP/EP300) bromodomain inhibition,
already shown to affect MM viability through transcriptional
suppression of IRF4 [24], recapitulated the observations ob-
tained using pan-BETi on MICA expression, adding novel
information on the possible immuno-therapeutic applica-
tions of this class of bromodomain inhibitors and transcrip-
tional coactivators in MM.
In conclusion, these findings provide new insights on
the immuno-mediated antitumor activities of BETi and
further elucidate the molecular mechanisms that regu-
late NK cell-activating ligand expression in MM.
Results
BETi upregulate MICA expression on human multiple
myeloma cells and enhance their recognition by NK cells
We investigated the ability of BETi to regulate the expres-
sion of NK cell-activating ligands in MM. To this purpose,
a panel of human MM cell lines [SKO-007(J3), RPMI-8226,
U266, ARP-1, and JJN3] were treated with a range of con-
centrations and at different times with JQ1 or I-BET151,
two small molecule bromodomain inhibitors displaying
potent binding affinity to BET family proteins [25], and ana-
lyzed for the expression of NKG2DLs and DNAM-1Ls, by
FACS analysis and qRT-PCR. As shown in Fig. 1a (and
Additional file 1), these drugs upregulated the basal expres-
sion of the NKG2D ligand MICA in different MM cell
lines, with no significant effects on MICB and PVR/CD155
levels. Concerning the other NKG2D and DNAM-1/
CD226 ligands, SKO-007(J3) cells express low or undetect-
able levels of ULBP2/5/6 or ULBP1, ULBP3, and Nec-2 re-
spectively and the treatment with BETi did not modify
their cell surface levels (Additional file 2). These treatments
did not affect the cell viability of these cell lines after 72 h
treatment, as assessed by PI staining (data not shown).
To examine whether the upregulation of MICA by BETi
could be associated with increased mRNA levels, total
RNA was isolated from the different cell lines exposed to
JQ1 or I-BET151 and analyzed by real-time qRT-PCR. As
shown in Fig. 1b and Additional file 3, we noticed a signifi-
cant increase of MICA mRNA levels in treated cells, in
particular after 48 h. In addition, we confirmed these re-
sults also in CD138+ MM cells isolated from the bone
marrow of MM patients (Table 1), showing higher cell sur-
face and mRNA levels of MICA following treatment with
JQ1 or I-BET151 (Fig. 2a, b). Of note, these drugs did not
show a significant effect on either MICB or PVR/CD155,
independently from the clinical status of the disease and
from basal expression levels.
To investigate the functional consequences of BETi-
induced changes of MICA expression, we analyzed the
lysosomal marker CD107a (a surrogate marker for granule
mobilization [26]) on NK cells isolated from healthy donors
against SKO-007(J3) cells, untreated or treated with JQ1 or
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I-BET151, by FACS analysis. As shown in Fig. 3a, basal
expression of CD107a on NK cells was enhanced when co-
cultured with SKO-007(J3) target cells exposed to BETi;
this effect was significantly inhibited by a blocking anti-
NKG2D monoclonal antibody (mAb), indicating that
stimulation of NK cell degranulation was dependent on
NKG2D activation. Accordingly, a higher capability of
degranulation was also observed in patient-derived NK cells
against BETi-treated autologous MM targets (Fig. 3b).
Altogether, these data indicate that treatment of human
MM cells with BETi enhances MICA cell surface and
mRNA expression, increasing their susceptibility to NK cell
recognition and killing.
BETi-induced upregulation of MICA in MM cells:
transcriptional mechanisms
To explore the possibility that BETi could increase MICA
expression at the transcriptional level, we analyzed the ef-
fects of BET proteins inhibition on SKO-007(J3) cells
transiently transfected with different MICA 5′-flank pro-
moter fragments, cloned upstream of a luciferase reporter
gene. As shown in Fig. 4a, JQ1 enhances the activity of
progressive promoter deletions (−3.2 kb to −270 bp from
the translation start site), delimiting a minimal fragment
spanning from −270 bp still responsive to BETi.
Downregulation of cMYC and of cMYC-dependent signa-
tures in MM cells (e.g., IRF4 and IRF4-dependent oncogenic
targets [2, 23]) have been proposed as pivotal effectors of
BETi-mediated activity in this cancer. In this regard, our
previous observation has identified IRF4 as an IMiD “drug-
gable” transcriptional repressor of NK cell-activating ligands
in MM cells [13], suggesting that similar transcriptional
pathways could be involved in BETi-treated cells.
We focused our attention on the immune-regulatory inter-
play mediated by these BET protein-regulated TFs and the
regulation of MICA expression in MM. As shown in
Fig. 4b–f and Additional file 4, we confirmed the capability of
BETi to modulate the expression of cMYC and IRF4 both in
SKO-007(J3) and in primary plasma cells isolated from MM
patients. In addition, compared with non-targeting short hair-
pin RNA (shRNA)-infected cells, cMYC shRNA-transduced
cells expressed higher MICA surface levels, whereas MICB
and PVR/CD155 membrane expression were unaffected
(Additional file 5A). Accordingly, real-time qRT-PCR analysis















































Fig. 1 BETi upregulate MICA expression in SKO-007(J3) human MM cells. a MICA, MICB, and PVR/CD155 cell surface expression were analyzed by flow
cytometry on SKO-007(J3) cells treated with JQ1 (0.5 μM) or I-BET151 (0.5 μM) for 72 h. Histograms represent MFI of specific mAb—MFI of isotype
control. The MFI of MICA, MICB, and PVR/CD155 was calculated based on at least four independent experiments and evaluated by paired Student t test
(*P < 0.05). In the insert, a representative histogram of MICA upregulation is shown. The grey-colored histograms represent basal expression of the
indicated ligand, while thick black histograms represent the expression after treatment with the drug. b Real-time PCR analysis of total mRNA obtained
from SKO-007(J3) cells, untreated or treated with the indicated BETi as described above for 24 and 48 h. Data, expressed as fold change units, were
normalized with GAPDH and referred to the untreated cells considered as calibrator and represent the mean of three experiments (*P < 0.05)
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showed that silencing of cMYC enhances MICA mRNA
expression and represses IRF4 (Additional file 5B).
IRF4 can positively and negatively regulate different genes
in part by binding to distinct DNA binding motifs and
through interactions with various additional transcription
factors [27]. As shown in Fig. 5a, SKO-007(J3) cells transi-
ently infected with a bicistronic lentivirus expressing IRF4
along with EGFP, displayed a significant lower induction of
MICA expression in the presence of JQ1 as compared to
cells infected with an empty control vector. Accordingly, the
selective abrogation of IRF4 transcriptional activity affects
MICA promoter in MM cells; as shown in Fig. 5b and con-
sistent with our previous study [13], transient transfection of
a truncated form of IRF4 (consisting of its N-terminal DNA
binding domain IRF4-DN/1-405) was sufficient to increase
MICA promoter activity, presumably by competing with
and inhibiting the endogenous repressive activity of IRF4 on
MICA. In addition, as shown in Fig. 5c, d and Additional
file 6A, the deletion of a putative IRF4 binding region in the
MICA/−270-bp fragment increased the transcriptional
activity. Interestingly, the same binding region is not fully
conserved in the MICB promoter, as already described for
the contiguous Ikaros binding elements in the same region.
Finally, as shown in Additional file 6B–D, treatment of
SKO-007(J3) cells with JQ1 only slightly decreased the
expression of the MICA repressors IKZF1 and IKZF3 [13]
as compared to the severe degradation induced by lenalido-
mide (via cereblon-CRL4) [28, 29], suggesting that the up-
regulation of MICA was mainly dependent on IRF4
downregulation. Interestingly, the combined treatment JQ1
+ lenalidomide further increased the expression of MICA
and repressed IRF4, suggesting that cereblon-mediated
degradation of IKZF1/3 cooperates with BETi-mediated
repression of IRF4 in this context (Additional file 6E, F).
Thus, MICA mRNA expression and promoter activity
are enhanced by BETi via a mechanism dependent on IRF4
downregulation.
Cross-talk BETi/miR-125b/IRF4 and regulation of MICA
expression in MM cells
Targeting deregulated microRNAs (miRNAs) is emerging
as a novel promising therapeutic approach against a num-
ber of cancers, including MM. Indeed, replacement of
tumor suppressor miRNAs by synthetic oligonucleotides
(miRNA mimics) offers a new therapeutic opportunity to
restore a loss of function or to regulate pathways involved
in the control of cancer progression [30, 31].
The microRNA-125b-5p (miR-125b) is commonly
deregulated in cancer, where its expression is generally re-
pressed by the activity of cMYC [32]; however, its function
diverges in different malignancies with dependence on the
molecular contexts [32]. Noteworthy, recent findings have
shown that the expression of IRF4 is modulated by miR-
125b-5p in MM cell lines or in patient-derived MM cells,
and enforced expression of miR-125b-5p can affect cell
growth and survival via downregulation of IRF4 and
impairment of its downstream signaling, indicating that
miR-125b is a tumor suppressor in MM [23].
In agreement with the studies mentioned above, our
observations show that treatment of MM cells with BETi in-
duces the upregulation of miR-125b-5p and this correlates
with the inhibition of cMYC expression (Fig. 6a, b). In the
same experimental setting, we confirmed the repression of
IRF4 and the induction of MICA mRNA (Additional file
7A, B). Accordingly, lentiviral-mediated overexpression of
this miRNA in SKO-007(J3) cells upregulates cell surface
and mRNA levels of MICA (Fig. 6c, d) and inhibits the ex-
pression of IRF4 (Fig. 6e), highlighting an additional/overlap-
ping miR-mediated immunoregulatory pathway for MICA
expression associated with BET proteins inhibition in MM.
BETi-induced upregulation of MICA in MM cells: role of BRD4
Recent studies have recognized the important role of the
BET family member BRD4 at super enhancer regions in-
volved in the regulation of specific oncogenes in different
cancers, including MM [2, 4, 33–37], and highlighted the
feasibility of blocking its function using BETi. However, a
potential problem with the use of small molecule inhibi-
tors is their reversible binding and significant systemic
Table 1 Clinical parameters of MM patients
Patient Sex/age Clinical state Monoclonal Ig % PCs in BM
1 F/42 Onset IgG-k 52
2 M/71 Relapse IgG-L 29
3 M/52 Onset IgA-k 30
4 M/73 Smoldering IgG-L 22
5 F/73 Smoldering IgA-L 34
6 M/50 Onset IgG-L 60
7 F/68 Relapse IgG-L 19
8 M/75 Relapse Micro-k 90
9 M/58 Onset IgG-k 60
10 F/46 Onset IgG-L 67
11 M/75 Relapse IgG-k 32
12 M/71 Relapse IgG-k 52
13 F/78 Relapse IgG-k 51
14 M/68 Relapse IgG-k 44
15 M/75 Onset IgG-L 24
16 F/54 Onset IgG-L 34
17 F/61 Relapse IgG-L 38
18 F/78 Onset IgG-k 40
19 M/73 Smoldering IgG-λ 13
20 M/71 Onset IgG-k 60
Patients were classified according to the status of disease. The percentage of
plasma cells in the BM and monoclonal Ig is indicated
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drug concentrations and/or continuous exposures are
often required to ensure sufficient functional inhibition.
Recently, novel small molecule-induced protein degrad-
ation strategies have been proposed for targeting undrug-
gable targets. In particular, the proteolysis targeting
chimeras (PROTACs) are able to recruit targeted proteins
to the E3 ubiquitin ligases for ubiquitination and subse-
quent proteasome-mediated degradation [38–41].
In order to better investigate the role of BRD4 in BETi-
mediated upregulation of MICA and the possibility to
target its function using a protein degradation strategy, we
treated MM cells with ARV-825, a novel PROTAC consist-
ing of a classic BRD4 binding moiety (triazolodiazepine
acetamide class in the BETi OTX015) and the compound
pomalidomide, a third-generation immunomodulatory drug
able to bind to the E3 ubiquitin ligase cereblon [42] con-
nected by a flexible polyethylene glycol linker (Additional
file 8). With this structure, ARV-825 has the ability to
recruit BRD4 to cereblon, resulting in the rapid and
efficient degradation of the former via the proteasome [43].
As shown in Fig. 7a, treatment of SKO-007(J3) cells with
ARV-825 induced a strong degradation of BRD4 that was
reverted in the presence of lenalidomide (a competitor for
binding to cereblon). In the same experimental setting,
ARV-825 significantly downregulated the expression of
IRF4 and cMYC (Fig. 7b–d) and upregulated the expression
of MICA (cell surface and mRNA), similarly to what
observed in the presence of JQ1 or I-BET151 (Fig. 7e–g).
We confirmed these results also in CD138+ MM cells
isolated from the bone marrow of MM patients, showing
Fig. 2 Upregulation of MICA expression on patient-derived PCs upon treatment with BETi. a MICA, MICB, and PVR/CD155 cell surface expression
was analyzed by flow cytometry on patient-derived MM cells treated with the indicated BETi for 72 h. For each treatment, value ratio between
MFI of specific mAb and MFI of isotype control is reported (*P < 0.05). b Real-time PCR analysis of total mRNA obtained from purified CD138+ cells
untreated or treated with JQ1 or I-BET151 for 48 h in complete medium supplemented with 20 ng/ml IL-3 and 2 ng/ml IL-6. Data, expressed as
fold change units, were normalized with GAPDH and referred to the untreated cells considered as calibrator. Myeloma cells were selected using
anti-CD138 magnetic beads and more than 95% of the purified cells expressed CD138 and CD38
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higher cell surface levels of MICA following treatment with
ARV-825 (Fig. 7h).
Moreover, the role of BRD4 was further confirmed by
shRNA interference (Additional file 9A, B). Since stable
BRD4 depletion is cytotoxic for myeloma cells, in these
experiments were used transient infections. Compared with
non-targeting shRNA-infected cells, BRD4 shRNA-
transduced cells expressed higher MICA cell surface levels.
Enhancing bromodomain selectivity: MICA expression is
upregulated by bromodomain inhibition of the
transcriptional coactivators EP300/CBP in MM cells
Preclinical evidence of the antitumor efficacy of BETi in re-
fractory hematological malignancies, including MM, inves-
tigated the action of drug levels that are achievable in vivo,
with sufficient data showing acceptable toxicity. However,
significant off-target effects have been described, rising con-
cern on the safety consequences of BET inhibition.
Given the broad involvement of BET proteins in tran-
scriptional regulation, improvement of the selectivity of
these compounds would restrict the number of genes
potentially affected, increasing specific targeting to avoid
adverse effects in the clinic [44].
In the last few years, selective and highly potent chemical
probe compounds targeting the bromodomains of CBP/
EP300 (CBP/EP300-BRi) have been developed (e.g., SGC-
CBP30 and I-CBP112), with high selective affinity for the
bromodomains of CBP/EP300 over other bromodomains
(greater than 30-fold selectivity of CBP30 for CBP and
EP300 compared with other bromodomains) [24].
CBP and EP300 are highly homologous bromodomain-
containing transcriptional coactivators that regulate a num-
ber of important cellular events through their acetyltransfer-
ase activity. Genetic studies in mice and analysis of human
cancer mutations and translocations have implicated CBP/
EP300 in cancer, but the role of the bromodomain in the
a
b
Fig. 3 BETi increase susceptibility of MM cells to NK cell recognition and degranulation. a NK cells, prepared from PBMCs of healthy donors, were
incubated with SKO-007(J3) cells, untreated or treated with the indicated BETi for 72 h as described above, and used as target cells in a degranulation assay.
The assay was performed at the effector/target (E:T) ratio of 2.5:1. After 2 h at 37 °C, cells were stained with anti-CD56, anti-CD3, and anti-CD107a mAbs. Cell
surface expression of CD107a was analyzed on FSC/SSC-gated and CD56+CD3− cells. In order to evaluate the role of NKG2D, the assay was performed in
parallel treating NK cells with a blocking anti-NKG2D antibody. Percentage of CD107a positive cells was calculated based on five independent experiments
and evaluated by paired Student t test (*P< 0.05). b BETi increase susceptibility of patient-derived MM PCs cells to autologous NK cell recognition and
killing. CD138− bone marrow cells, cultured for 2 days in complete medium supplemented with IL-2 (200 U/mL), were incubated with purified autologous
myeloma cells, untreated or treated with JQ1 for 48 h, and used as target cells in a degranulation assay. The assay was performed at the effector/target
(E:T) ratio of 2.5:1. After 2 h at 37 °C, cells were stained with anti-CD56, anti-CD3, anti-CD16, and anti-CD107a mAbs. Cell surface expression of CD107a was
analyzed on CD56+CD16+CD3− cells. Results obtained from two patients (P16 and P17) are represented
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normal and pathological function of CBP/EP300 has not
been extensively studied.
Noteworthy, CBP/EP300 bromodomain inhibition has
been shown to target a more limited subset of hematologic
cell lines, with a bias toward MM/plasmacytoma cell lines
and enrichment of signatures for pathways important in
MM growth and survival. This increased selectivity was dis-
tinct from the effects of pan-BET inhibition, targeting the
IRF4-MYC network at different nodes and, interestingly, via
the direct focused transcriptional inhibition of IRF4 [24].
Our observations indicate that treatment of human MM






Fig. 4 MICA promoter activity is enhanced by BETi in MM cells. a SKO-007(J3) cells were cotransfected with 3 μg of the indicated luciferase reporter
vector + 1 μg of pRL-TK expression vector as described in the “Methods” section. Four hours after transfection, cells were left untreated (−) or were
stimulated with 0.5 μM JQ1 for 48 h. Cells were then harvested and protein extracts were prepared for the luciferase and Renilla assays. Results are
expressed as relative luciferase activity normalized to protein concentration as well as to Renilla activity produced off the internal control plasmid and
represent the mean value of four independent experiments (*P < 0.05). b–e BETi represses cMYC and IRF4 mRNA expression in SKO-007(J3) MM cells.
Real-time PCR analysis of total mRNA obtained from SKO-007(J3) cells, untreated or treated with the indicated BETi as described above for 24 and 48 h.
Data, expressed as fold change units, were normalized with GAPDH and referred to the untreated cells considered as calibrator and represent the
mean of three experiments (*P < 0.05). f Lysates of SKO-007(J3) cells untreated or treated with BETi for 24 or 48 h were subjected to Western blotting
using anti-IRF4 and actin antibodies. The proteins transferred to nitrocellulose membranes were stained with Ponceau to verify that similar amounts of
proteins had been loaded in each lane. Data are representative of one out of three independent experiments
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selectively upregulates cell surface and mRNA expression of
MICA with no significant effects on MICB or PVR/CD155
(Fig. 8a–c), suggesting an immunomodulatory potential
associated with the specific CBP/EP300 bromodomain in-
hibition. In agreement with the above-described data, SCG-
CBP30 repressed the expression of IRF4 and cMYC in our
experimental system, although to a lesser extent than JQ1
(Fig. 8d, e), suggesting that significant upregulation of MICA
can be achieved in MM cells also in the presence of inhibi-
tors able to affect the function of selected bromodomains,
specifically involved in the control of the IRF4-regulated
transcriptional network. Interestingly, as shown in Fig. 8f,
treatment of SKO-007(J3) cells with a specific-competitive
histone acetyltransferase CBP/EP300 inhibitor (C646) [45,
46] was able to replicate a similar upregulation of MICA in
our experimental system, thus identifying CBP/EP300 as
novel regulators of this gene in MM.
Discussion
In this study, we investigated the effects of BETi on NK
cell-activating ligand expression in MM cells.
The data shown in this manuscript indicate that the
mRNA and cell surface expression of the NK cell-
activating ligand MICA is upregulated in BETi-treated hu-
man MM cells lines and in MM cells isolated from the
bone marrow of MM patients, independently from the
Fig. 5 IRF4 is a repressor of MICA promoter activity in MM cells. a MICA cell surface expression was analyzed by flow cytometry on pEF.CMV.EGFP-IRF4-
lentivirus (or pEF.CMV.EGFP control virus) infected SKO-007(J3) cells (72 h), by gating on GFP+ cells as indicated in the panel. After infection, cells were
separated into different drug treatment groups, untreated or treated with JQ1 (0.5 μM). The ratio MFI between JQ1-treated on untreated cells is shown
in a representative experiment. b SKO-007(J3) cells were cotransfected with 3 μg of the indicated luciferase reporter vector and pRL-TK as described
above + 1 μg of an expression vector encoding a truncated form of the human IRF4, IRF4-DN, or an empty control vector pcDNA3. After 48 h, cells
were harvested and protein extracts were prepared for the luciferase and Renilla assays. Results are expressed as relative luciferase activity normalized
to protein concentration as well as to Renilla activity produced off the internal control plasmid and represent the mean value of four independent
experiments (*P < 0.05). c SKO-007(J3) cells were transfected with 3 μg of the indicated luciferase reporter vector and pRL-TK as described above. After
48 h, cells were harvested and protein extracts were prepared for the luciferase and Renilla assays. Results are expressed as relative luciferase activity
normalized to protein concentration as well as to Renilla activity produced off the internal control plasmid and represent the mean value of four
independent experiments (*P < 0.05). d Schematic representation of the IRF4 response element deleted in the mutant promoter MICA/-270-DEL
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clinical stage of the disease and from basal level of expres-
sion of this ligand. The functional implication of this up-
regulation is an increased degranulation of NK cells
contacting drug-treated target cells, with a mechanism
dependent on the activation of the NKG2D receptor, either
using cultivated NK cells from healthy donors or autolo-
gous patient-derived NK cells (Fig. 3).
Mechanistically, we found that treatment of MM cells
with BETi upregulates the activity of the MICA promoter;
moreover, using progressive deletions, we identified a
minimal promoter fragment spanning from −270 bp still
responsive to BETi (Fig. 4).
Treatment of MM cells with BETi downregulated the ex-
pression of cMYC and IRF4 (Fig. 4 and Additional file 4), the
latter being a transcriptional target of cMYC, and recently
identified by our laboratory as a “IMiDs druggable” transcrip-
tional repressor of MICA in MM cells [13]. In this context,
cMYC shRNA-transduced cells expressed higher MICA
surface levels, whereas MICB and PVR/CD155 membrane
expression were unaffected. Accordingly, real-time qRT-PCR
analysis showed that silencing of cMYC enhances MICA
mRNA expression and represses IRF4 (Additional file 5).
IRF4 can positively and negatively regulate different
genes, in part by binding to distinct DNA binding motifs
and through interaction with various additional transcrip-
tion factors [27]. Its C-terminal transactivation domain is
critical for gene activation, while the mechanism(s) re-
sponsible for gene repression are not well defined. In our
experimental system, the overexpression of IRF4 by
lentiviral-mediated transduction partially abrogated the
induction of MICA after treatment with BETi. Moreover,
the overexpression of a dominant negative form of IRF4
induced significant upregulation of MICA promoter, and






Fig. 6 miR-125b upregulates MICA expression in SKO-007(J3) human MM cells. a Treatment with JQ1 (48 h) increases miR-125b expression in SKO-007(J3)
cells. b As a control, the same mRNAs were analyzed for cMYC expression. Data of real-time PCR analysis, expressed as fold change units, were normalized
with (U6) or GAPDH respectively and referred to the untreated cells considered as calibrator and represent the mean of three experiments (*P< 0.05). c
Overexpression of pre-miR-125b increases MICA cell surface expression in SKO-007(J3) cells. MICA, MICB, and PVR/CD155 surface expression were analyzed
by flow cytometry on pre-miR-control/GFP or pre-miR-125b/GFP lentivirus transiently infected SKO-007(J3) cells (72 h), by gating on GFP+ cells. The MFI of
MICA, MICB, and PVR/CD155 was calculated based on at least four independent experiments and evaluated by paired Student t test (*P< 0.05). d, e
Overexpression of pre-miR-125b increases MICA mRNA expression and represses IRF4 mRNA expression in SKO-007(J3) cells. Real-time PCR analysis of total
mRNA obtained from SKO-007(J3) cells infected with pre-miR-control or pre-miR-125b lentivirus. Data, expressed as fold change units, were normalized
with GAPDH and referred to the pre-miR-control infected cells considered as calibrator and represent the mean of three experiments (*P< 0.05)
Abruzzese et al. Journal of Hematology & Oncology  (2016) 9:134 Page 10 of 19
minimal MICA/-270 bp promoter fragment enhanced its
activity, further confirming the repressive activity of IRF4
at this level (Fig. 5).
Interestingly, the expression of IRF4 has been linked
to the activity of the transcription factors IKZF1 and









Fig. 7 The PROTAC/BRD4 degrader, ARV-825, upregulates MICA expression in SKO-007(J3) cells. a Treatment of SKO-007(J3) cells with ARV-825 induced
a strong degradation of BRD4 that was reverted in the presence of lenalidomide. Lysates of SKO-007(J3) cells, untreated or treated with ARV-825
(0.2 μM), lenalidomide (10 μM), or the combination of the two drugs for 24 h, were subjected to Western blotting using anti-BRD4 or anti-p85 anti-
bodies. b ARV-825 inhibits the expression of IRF4. Lysates of SKO-007(J3) cells, untreated or treated with the indicated (μM) concentrations of ARV-825
for 48 h, were subjected to Western blotting using anti-IRF4 or anti-actin antibodies. The proteins transferred to nitrocellulose membranes were stained
with Ponceau to verify that similar amounts of proteins had been loaded in each lane. Data are representative of one out of three independent
experiments. c, d ARV-825 inhibits mRNA expression of IRF4 and cMYC. Real-time PCR analysis of total mRNA obtained from SKO-007(J3) cells,
untreated or treated with the indicated (μM) concentrations of ARV-825 for 48 h. Data, expressed as fold change units, were normalized with GAPDH
and referred to the untreated cells considered as calibrator and represent the mean of three experiments (*P < 0.05). e, f MICA, MICB, and PVR/155 cell
surface expression were analyzed by flow cytometry on SKO-007(J3) cells treated with the indicated concentrations of ARV-825 for 72 h. The MFI of
MICA, MICB, and PVR/155 were calculated based on at least four independent experiments and evaluated by paired Student t test (*P < 0.05). In e, a
representative histogram of MICA upregulation is shown. The grey-colored histograms represent basal expression of the indicated ligand, while thick
black histograms represent the expression after treatment with the drug. Data are representative of one out of four independent experiments. g
ARV-825 increases mRNA expression of MICA in SKO-007(J3) cells. Real-time PCR analysis of total mRNA obtained from SKO-007(J3) cells, untreated or
treated with the indicated (μM) concentrations of ARV-825 for 48 h. Data, expressed as fold change units, were normalized with GAPDH and referred
to the untreated cells considered as calibrator and represent the mean of three experiments (*P < 0.05). h MICA cell surface expression was analyzed
by flow cytometry on patient-derived MM cells treated with the indicated ARV-825 for 72 h. The grey-colored histograms represent basal expression,
while thick black histograms represent the expression after treatment with the drug
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MICA gene expression [13]. However, in our experimental
system, treatment of SKO-007(J3) cells with JQ1 only
slightly decreased the expression of the IKZF1 and IKZF3
(Additional file 6A–C); as a control, lenalidomide com-
pletely abrogated the expression of these two transcription
factors, further suggesting that the upregulation of MICA
mediated by BETi was mainly dependent on the repres-
sion of IRF4. Noteworthy, as shown in Additional file
6E, the combination of the two treatments (lenalido-
mide + BETi) further increased the expression of MICA,
suggesting the possibility that low-dose combinations of
IMiDs with BETi could display additional or synergis-
tic activities in MM, as already shown in primary ef-
fusion lymphoma (PEL) preclinical data, where the
simultaneous targeting of IKZF1-IRF4-MYC increased
the cytotoxic effect as compared with either agent
alone [48]. In this context, in MM, the combined ac-
tivities of these two classes of drugs could be able to
improve direct cytotoxicity and, at the same time, to
enhance the expression of NK cell-activating ligands.








Fig. 8 CBP/EP300-BRi upregulate MICA expression in SKO-007(J3) MM cells. a, b MICA, MICB, and PVR/CD155 cell surface expression were analyzed
by flow cytometry on SKO-007(J3) cells treated with CBP30 (1 or 2 μM) for 72 h. In a, a representative histogram of MICA upregulation compared to
MICB and PVR/CD155 is shown (2 μM). The MFI of MICA, MICB, and PVR/CD155 was calculated based on at least four independent experiments and
evaluated by paired Student t test (*P < 0.05). c Real-time PCR analysis of total mRNA obtained from SKO-007(J3) cells, untreated or treated with CBP30
or JQ1 as described above for 48 h. Data, expressed as fold change units, were normalized with GAPDH and referred to the untreated cells considered
as calibrator and represent the mean of three experiments (*P < 0.05). d, e CBP/EP300-BRi inhibits mRNA expression of IRF4 and cMYC. Real-time PCR
analysis of total mRNA obtained from SKO-007(J3) cells, untreated or treated with CBP30 or JQ1 as described above, for 48 h. Data, expressed as fold
change units, were normalized with GAPDH and referred to the untreated cells considered as calibrator and represent the mean of three experiments
(*P < 0.05). f MICA cell surface expression was analyzed by flow cytometry on SKO-007(J3) cells treated with C646 (5 μM) for 72 h. The MFI of MICA was
calculated based on at least three independent experiments and evaluated by paired Student t test (*P < 0.05)
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Several reports have shown that different cellular miR-
NAs regulate NKG2DL genes, and the expression of several
miRNAs that target NKG2D ligands is regulated by im-
mune stimuli or activated p53, suggesting a complex regu-
latory role [49–51]. In MM, miRNA dysregulation has been
shown to increase from MGUS to MM patients and spe-
cific miRNA signatures were determined [52, 53]. In this
regard, recent findings revealed a peculiar role played by
miR-125b in MM. Differently from other hematologic
malignancies, this miRNA displays tumor suppressor activ-
ities in MM, affecting growth and survival, impairing the
expression of IRF4 and its downstream targets [23]. In our
experimental system, treatment of MM cells with BETi
induced upregulation of miR-125b-5p and this correlated
with downregulation of cMYC, as already described in
different malignancies [54]. Lentiviral-mediated overexpres-
sion of this miR-inhibited the expression of IRF4 and up-
regulated cell surface and mRNA levels of MICA (Fig. 6),
suggesting an additional miR-mediated immune-regulatory
network associated with BET inhibition, cMYC, IRF4, and
MICA expression. Interestingly, recent findings indicate
that synthetic miR-125b-5p mimics can induce anti-
myeloma activity in vivo, with no significant toxic effects
(e.g., PBMC viability), suggesting a promising therapeutic
activity [23]. Further experiments will be needed to investi-
gate the possibility to extend this therapeutic strategy to
harness the cytotoxic activity of NK cells against MM via
MICA/NKG2D.
BETi are currently being evaluated in different clinical tri-
als for a range of malignancies, due to their ability to sup-
press the expression of otherwise undruggable downstream
transcription factors; however, the molecular and cellular
mechanisms that regulate sensitivity or the resistance to
these drugs remain largely unknown and the identification
of relevant predictive biomarkers of response is needed [55].
Among the potential problems connected with the use
of BETi in therapy is the finding that selected drugs (e.g.,
JQ1 or OTX015) have been shown to induce significant
accumulation of BRD4 protein in Burkitt’s lymphoma cell
lines; in addition, similar observations have been reported
in lung and prostate cancer cell lines [43, 56]. It has been
suggested that binding of BETi to BRD4 could result in a
conformational change leading to increased stability of
this protein and/or altered BRD4 accessibility to the en-
dogenous cellular degradation machinery. Moreover, this
increase of BRD4 levels and the reversible nature of in-
hibitor binding could preclude efficient BRD4 inhibition
and repression of cMYC [43], thus limiting the potential
benefit of therapeutic intervention at clinically achievable
concentrations of these inhibitors.
Our data indicate that treatment of SKO-007(J3) cells
with the PROTAC BRD4-degrader ARV-825 (sub-micro-
molar concentrations) induced a strong cereblon-mediated
degradation of BRD4 with significant downregulation of
IRF4-cMYC and upregulation of MICA. In this context, the
role of BRD4 was further confirmed by direct shRNA inter-
ference (Additional file 9). Thus, BRD4-PROTACs could
represent an additional promising strategy to efficiently
block the BRD4/cMYC/IRF4 axis, increasing at the same
time the expression of MICA in MM.
A different problem concerning the use of BETi in ther-
apy could be related to off-target effects that they can
induce. For example, the pan-BET inhibitory activity of
JQ1 has been shown to inhibit testicular BRDT to cause
reversible testicular atrophy and infertility [57], and
thrombocytopenia together neutropenia were the dose-
limiting toxicities observed in phase I clinical trials with
the oral BET-BRD inhibitor OTX015 [6, 7]. Noteworthy,
the proposed/tolerated dose of this inhibitor (40 to 80 mg
once daily) has been shown to reach plasma drug levels in
the micromolar range [6, 7], a concentration able to in-
duce a significant upregulation of MICA expression in our
experimental setting (Additional file 10).
Thus, improvement of BETi activity toward selected
members of this family of regulators would restrict the
number of genes potentially affected, improving specific
targeting [44].
In this regard, specific inhibition of CBP/EP300 bromo-
domains has been shown to target a more limited subset
of hematological malignant cells, with a bias toward
multiple myeloma/plasmacytoma cell lines. This increased
selectivity was distinct from the effects of pan-BET inhib-
ition, targeting the IRF4-cMYC network at different nodes
and, interestingly, via direct focused transcriptional inhib-
ition of IRF4 [24]. Our observations indicate that treat-
ment of MM cells with micromolar concentrations of a
CBP/EP300-BRi (SGC-CBP30) repressed the expression
of IRF4 and upregulated cell surface and mRNA expres-
sion of MICA (Fig. 8), suggesting an immunomodulatory
potential associated with the selective inhibition of the
CBP/EP300 bromodomain. The higher affinity for the bro-
modomains of CBP/EP300 over other bromodomains
(greater than 30-fold selectivity of CBP30 for CBP/EP300
compared with other bromodomains) is predicted to re-
strict possible unwanted off-target effects [24, 58].
Interestingly, a distinct association between abnormal
EP300 and different malignancies has been characterized
in the last years [59–62]. Indeed, in addition to growth ar-
rest, EP300 is involved in G1/S transition in human cancer
cells and its inhibition can induce block of progression to
the S-phase and apoptosis [45, 61]. The finding reported
here that a specific histone acetyltransferase CBP/EP300
inhibitor (C646) is able to replicate a similar upregulation
of MICA (at least in our experimental system), identifies
CBP/EP300 as possible novel and druggable regulator(s)
of this gene in MM, via specific classes of small molecule
probes. Further experiments will be needed to better in-
vestigate the role of CBP/EP300 as a regulator of MICA
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gene expression in patient-derived MM cells and in other
hematological tumors.
Conclusions
In summary, we propose a model in which the functional
inhibition of BET proteins or CBP/EP300 using specific
inhibitors can increase the expression of the NKG2D-
activating ligand MICA in MM cells via different inte-
grated pathways involving the axis cMYC-IRF4-miR-125b.
These data add novel information on the immunomodu-
latory activities displayed by BETi and CBP/EP300-BRi,
small molecules already known to modulate the expression
of inflammatory cytokines in autoimmunity, to inhibit
deregulated osteoclastogenesis during cancer progression
and to block Th17 and Treg function, two important T cell
subsets in MM pathobiology [58, 63–67].
The possibility to obtain a much more restricted/tai-
lored effect on gene expression and immunomodulation
using novel BETi or CBP/EP300-BRi [58] could further
improve direct and immuno-mediated antitumor activity
of bromodomain inhibition in MM and add novel infor-
mation on the molecular mechanisms that regulate NK
cell-activating ligand expression.
Methods
Cell lines and clinical samples
Human myeloma cell lines SKO-007(J3), U266, ARP-1,
and RPMI-8226 were kindly provided by Prof. P. Trivedi
(University of Rome, Sapienza, Italy). The human MM cell
lines JJN-3 was kindly provided by Prof. N. Giuliani (Uni-
versity of Parma, Italy). These cell lines were maintained
at 37 °C and 5% CO2 in RPMI 1640 supplemented with
10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, and
100 U/ml streptomycin (complete medium). The human
293T embryonic kidney cells were purchased from ATCC
and were maintained in Dulbecco’s modified Eagle’s sup-
plemented with 10% FCS. All cell lines were mycoplasma-
free (EZ-PCR Mycoplasma Test Kit; Biological Industries).
Bone marrow samples from patients with MM were
managed at the Division of Hematology, Department of
Cellular Biotechnologies and Hematology, University of
Rome, Sapienza, Italy (Table 1). Informed consent in
accordance with the Declaration of Helsinki was obtained
from all patients, and approval was obtained from the
ethics committee of the Sapienza University of Rome. The
bone marrow aspirates were processed as already described
in [68]. In some experiments, myeloma cells were selected
using anti-CD138 magnetic beads (Miltenyi Biotec). More
than 95% of the purified cells expressed CD138 and CD38.
Reagents and antibodies
The bromodomain inhibitors JQ1 and I-BET151 (GSK
1210151A), OTX015, and C646 (a specific-competitive
histone acetyltransferase CBP/EP300 inhibitor) were
purchased from Selleckchem.com. The selective inhibitor
of the bromodomain-containing transcription factors
CREBBP (CBP) and EP300, SGC-CBP30, was purchased
from Tocris Bioscience. Lenalidomide was purchased from
BioVision Inc. The hetero-bifunctional PROTAC (proteoly-
sis targeting chimera) ARV-825 was purchased from
Chemietek. These drugs were dissolved in dimethylsulph-
oxide (DMSO) and stored at −20 °C until use. The final
concentration of DMSO in all experiments was <0.1%. The
following mAbs were used for immunostaining or as
blocking Abs: anti-MICA (MAB159227), anti-MICB
(MAB236511), anti-ULBP-1 (MAB170818), anti-ULBP-2/
5/6 (MAB165903), anti-ULBP-3 (MAB166510), and anti-
NKG2D (MAB149810) from R&D System, anti-PVR/
CD155 (SKII.4) kindly provided by Prof. M. Colonna
(Washington University, St. Louis, MO), anti-MHCI (W6/
32) provided by Dr. P. Giacomini (Regina Elena Cancer In-
stitute, Rome, Italy), anti-CD56 (C218) mAb provided by
Dr. A. Moretta (University of Genoa, Genoa, Italy), APC
goat anti-mouse IgG (Poly4053), anti-CD56/PE (HCD56),
mouse IgG1/FITC, /PE or /APC isotype control (MOPC-
21) purchased from BioLegend. anti-CD3/FITC (SK7), anti-
CD56 (NCAM16.2), anti-CD107a/APC (H4A3), anti-
CD138-FITC (M15), anti-CD38-APC (HIT2), anti-nectin 2
(R2.525), and anti-CD16-PerCP-Cy5.5 (3G8) purchased
from BD Biosciences.
Flow cytometry and degranulation assay
SKO-007(J3), ARP-1, U266, JJN-3, and RPMI-8226 cells
were cultured in six-well tissue culture plates for 72 h at a
concentration of 2 × 105 cells/ml in the presence of the in-
dicated drug. The expression of the NKG2D and DNAM-1
ligands on MM cells was analyzed by immunofluorescence
staining using unconjugated mAbs, followed by secondary
GAM-APC. In all experiments, cells were stained with pro-
pidium iodide (PI) (1 μg/ml) in order to assess cell viability
(always higher than 90% after the different treatments).
Nonspecific fluorescence was assessed by using an isotype-
matched irrelevant mAb R&D System, followed by the
same secondary antibody. Fluorescence was analyzed using
a FACSCalibur flow cytometer (BD Biosciences), and data
were analyzed using FlowJo Flow Cytometric Data Analysis
Software (Tree Star, Inc). The analysis of ligands expression
on patient-derived plasma cells was performed by gating on
the CD138+ and CD38+ PC population.
NK cell-mediated cytotoxicity was evaluated using the
lysosomal marker CD107a as previously described [69].
As source of effector cells, we used primary NK cells
obtained from PBMCs isolated from healthy donors by
Lymphoprep–Nycomed gradient centrifugation and then
co-cultured for 10 days with irradiated (30 Gy) Epstein-
Barr virus (EBV)-transformed B cell line RPMI 8866 at
37 °C in a humidified 5% CO2 atmosphere, as previously
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described [69]. On day 10, the cell population was rou-
tinely more than 90% CD56+CD16+CD3−, as assessed by
immunofluorescence and flow cytometry analysis.
When patient-derived plasma cells were used as targets
(myeloma cells were selected using anti-CD138 magnetic
beads from Miltenyi Biotec), autologous CD138− bone
marrow cells were cultured for 2 days in complete
medium, supplemented with 200 U/ml IL-2, and used as
source of effector cells.
Drug-treated MM cell lines or patient-derived plasma
cells were washed twice in complete medium and incu-
bated with NK cells at effector/target (E:T) ratio of 2.5:1, in
a U-bottom 96-well tissue culture plate in complete
medium at 37 °C and 5% CO2 for 2 h. Thereafter, cells were
washed with PBS and incubated with anti-CD107a/APC (or
cIgG/APC) for 45 min at 4 °C. Cells were then stained with
anti-CD3/FITC, anti-CD56/PE, and anti-CD16/PerCP-
Cy5.5 to gate the CD3-CD56+ CD16+ NK cell population.
In some experiments, cells were pre-treated for 20 min at
room temperature with anti-NKG2D neutralizing mAbs or
a control Ab (anti-CD56). Fluorescence was analyzed using
a FACSCalibur flow cytometer (BD Biosciences), and data
were analyzed using FlowJo Flow Cytometric Data Analysis
Software (Tree Star).
Plasmids
MICA-270 bp promoter in pGL3-basic luciferase vector
(Promega Corp.) was generated as previously described
[68]. To generate the MICA promoter deletions MICA/
3.2 kb and MICA/1.2 kb, the appropriate deletion frag-
ments (Kpn-I/HindIII) were generated by PCR according
to standard methods from a human 3.2 kb-wild-type-
MICA/GFP reporter vector (kindly provided by Dr. Skov,
University of Copenhagen, Frederiksberg, Denmark) and
cloned in pGL3-basic luciferase vector. The primers used
to amplify PCR products using LongAmp Taq DNA Poly-
merase (New England BioLabs) are as follows:
cagatctggtaccagctcgagaccaacctgaccaac - MICA −3.2 kb-sen;
cagatctggtacctggtgggatagggtgaggagatc - MICA −1.2 kb-sen;
gaatgccaagcttggccccgacgtcgccaccctctc - MICA +39 bp-rev.
The mutant MICA promoter construct (MICA/-270-
DEL) was generated using Quick Change Site-Directed
Mutagenesis Kit Statagene, following the manufacturer’s
instructions, as described in [13]. All constructs were
verified by DNA sequence analysis.
The lentiviral vector pEF.CMV.EGFP-IRF4, encoding
the human IRF4, was generated by inserting a full-length
human IRF4 complementary DNA (cDNA) (obtained
from an expression vector pcDNA3-IRF4, kindly provided
by Dr. Hayashi H., Graduate School of Medical Sciences,
Nagasaki University, Japan) [70], in the lentivirus pEF.CM-
V.EGFP. The IRF4 dominant negative expression vector
IRF4-DN, encoding a truncated form of the human IRF4,
consisting of its N-terminal DNA binding domain (1-405),
was generated by inserting the mutant IRF4 cDNA in the
pcDNA3 expression vector [70].
The lentiviral copGFP vectors pMIRNA1/pre-miR-125b
and the pMIRNA1/control vector were purchased from
System Biosciences.
For knocking down cMYC and BRD4, we used the follow-
ing lentiviral vectors: pLKO.1-sh-cMYC (TRCN0000039642),
pLKO.1-sh-BRD4 (TRCN0000382028), and the control vec-
tor pLKO non-targeting shRNA MISSION™ (Sigma-Aldrich).
DNA transfections, virus production, and in vitro
transduction
Transfections of SKO-007(J3) cells were carried out using a
4D-Nucleofector System (Lonza). Where needed, cells were
transfected in single batches that were then separated into
different drug treatment groups, to decrease variations in
the experiments due to different transfection efficiency. A
pTK-Renilla expression vector was cotransfected to
normalize DNA uptake. After 3 h, cells were treated with
JQ1; after additional 40 h, cells were harvested and protein
extracts were prepared for the luciferase and Renilla assays.
Protein concentration was quantified by the BCA method
Pierce, Rockford. Luciferase and Renilla activity were quan-
tified using the Dual-Luciferase Reporter Assay and the
Glomax Multi Detection System (Promega), following the
manufacturer’s instructions.
For lentivirus production, Phoenix cells were transfected
with 5 μg of viral DNA using Lipofectamine Plus (Life
Technologies). The lentiviral vectors were cotransfected
together the packaging vectors pVSVG and psPAX2 into
293T cells using Lipofectamine Plus. After transfection, the
cells were placed in fresh medium. After a further 48-h
culture, virus-containing supernatants were harvested,
filtered, and used immediately for infections. Infections
were performed on 0.5 × 106 SKO-007(J3) cells in 2-ml
complete medium with polybrene (8 μg/ml) (hexadimethr-
ine bromide; Sigma-Aldrich) for 2 h. For GFP-expressing
viruses, the infection efficiency was measured by FACS ana-
lysis of GFP expression at day 3 after infection.
miRNA and mRNA detection, by quantitative real-time
polymerase chain reaction (qRT-PCR)
Total RNA was extracted using TRIZOL™ (Life Technolo-
gies), according to manufacturer’s instructions. The con-
centration and quality of the extracted total RNA was
determined by measuring light absorbance at 260 nm
(A260) and the ratio of A260/A280. Reverse transcription
was carried out in a 25-μl reaction volume with 2 μg of
total RNA according to the manufacturer’s protocol for M-
MLV reverse transcriptase Promega. cDNAs were ampli-
fied (TaqMan assays) in triplicate with primers for MICA
(Hs00792195_m1), IRF4 (Hs01056533_m1), MYC (Hs0015
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3408_m1), IKZF1 (Hs00958474_m1), IKZF3 (Hs00232
635_m1), and GAPDH (Hs03929097_g1) conjugated with
fluorochrome FAM (Applied Biosystems). The level of
expression was measured using Ct (threshold cycle).
The Ct was obtained by subtracting the Ct value of the
gene of interest from the housekeeping gene (GAPDH)
Ct value. In the present study, we used Ct of the un-
treated sample as the calibrator. The fold change was
calculated according to the formula 2-ΔΔCt, where
ΔΔCt was the difference between Ct of the sample
and the Ct of the calibrator (according to the formula,
the value of the calibrator in each run is 1). The analysis
was performed using the SDS version 2.4 software
(Applied Biosystems). miRNA quantification was per-
formed using TAQMAN® MICRORNA kit and U6snRNA
expression for normalization. Corresponding reverse
transcription and polymerase chain reaction primers for
U6snRNA and miR-125b were obtained from Applied
Biosystems. All PCR reactions were performed using an
ABI Prism 7900 Sequence Detection System (Applied
Biosystems).
Western blot analysis
For Western blot analysis, SKO-007(J3) cells were pelleted,
washed once with cold phosphate-buffered saline, resus-
pended in lysis buffer [1% Nonidet P-40 (v/v), 10% glycerol,
0.1% SDS, 0.5% sodium deoxycholate, 1 mM phenyl-
methyl-sulfonyl fluoride (PMSF), 10 mM NaF, 1 mM Na3
VO4, complete protease inhibitor mixture Roche in PBS],
and subsequently incubated 30 min on ice. The lysate was
centrifuged at 14,000 g for 15 min at 4 °C, and the super-
natant was collected as whole cell extract. Protein concen-
tration was determined by the BCA method Pierce. Thirty
to 50 μg of cell extract was run on 10% denaturing SDS-
polyacrylamide gels. Proteins were then electroblotted onto
nitrocellulose membranes (Schleicher & Schuell), stained
with Ponceau to verify that similar amounts of proteins had
been loaded in each lane, and blocked in 5% BSA in TBST
buffer. Immunoreactive bands were visualized on the
nitrocellulose membranes, using horseradish-peroxidase-
coupled goat anti-rabbit or goat anti-mouse immunog-
lobulins and the ECL detection system (GE Healthcare
Amersham), following the manufacturer’s instructions.
Antibodies against β-actin, IRF4 (H-140), Ikaros (H-100),
and Aiolos (L-15) were purchased from Santa Cruz
Biotechnology. Antibody against Brd-4 was purchased from
Abcam. Antibody against the p85 subunit of PI3 kinase was
purchased from Millipore.
Statistical analysis
Error bars represent SD. Data have been evaluated by
paired Student t test and a level of P < 0.05 was consid-
ered to be statistically significant.
Additional files
Additional file 1: BETi upregulate MICA expression in different human
MM cell lines. MICA, MICB, and PVR/CD155 cell surface expression were
analyzed by immunofluorescence and flow cytometry on RPMI-8226,
U266, ARP-1, and JJN3, respectively, after a 72 h treatment with JQ1.
The MFI of MICA, MICB, and PVR/CD155 was calculated based on at least
four independent experiments and evaluated by paired Student t test
(*P < 0.05). In the insert, a representative histogram of MICA upregulation
is shown. The grey-colored histograms represent basal expression of the
indicated ligand, while thick black histograms represent the expression
after treatment with the drug. (TIF 3542 kb)
Additional file 2: ULBPs and Nec-2 ligand expression on SKO-007(J3) cells
following treatment with JQ1. ULBPs and Nec-2 surface expression were
analyzed by immunofluorescence and flow cytometry on SKO-007(J3) cells
treated with JQ1 as described above for 72 h. The grey-colored histograms
represent basal expression of the indicated ligand, while thick black
histograms represent the expression after treatment with the drug. Data are
representative of three independent experiments. (TIF 3116 kb)
Additional file 3: BETi upregulate MICA mRNA expression in different
human MM cell lines. Real-time PCR analysis of total mRNA obtained
from the indicated cell lines, untreated or treated with the indicated BETi
for 24 and 48 h. Data, expressed as fold change units, were normalized
with GAPDH and referred to the untreated cells considered as calibrator
and represent the mean of three experiments (*P < 0.05). (TIF 5669 kb)
Additional file 4: IRF4 and cMYC mRNA expression are inhibited in
patient-derived MM PCs upon treatment with BETi. Real-time PCR analysis
of total mRNA obtained from purified CD138+ cells untreated or treated
with I-BET151 for 48 h in complete medium supplemented with 20 ng/
ml IL-3 and 2 ng/ml IL-6. Data, expressed as fold change units, were
normalized with GAPDH and referred to the untreated cells considered
as calibrator. (TIF 4030 kb)
Additional file 5: shRNA interference of cMYC upregulates MICA expression
in SKO-007(J3) cells. MICA, MICB and PVR/CD155 cell surface expression were
analyzed by flow cytometry on pLKO control (non-targeting) or pLKO-cMYC-
lentivirus-infected SKO-007(J3) cells (72 h). (A) Representative histogram of
MICA upregulation is shown. Data are representative of one out of three
independent experiments. (B) Total RNAs were isolated from infected cells
(48 h) for Real-time qRT-PCR analysis. Data, expressed as fold change units,
were normalized with GAPDH and referred to the cells infected with non-
target shRNA considered as calibrator and represent the mean of three
experiments (*P< 0.05). (TIF 5600 kb)
Additional file 6: (A) Schematic representation of IKAROS and IRF4
response elements of MICA and MICB promoters. (B, C) Effect of BETi on IKZF1
and IKZF3 mRNA expression in SKO-007(J3) MM cells. Real-time PCR analysis
of total mRNA obtained from SKO-007(J3) cells, untreated or treated with JQ1
(0.5 μM) or lenalidomide (5 μM) for 48 h. Data, expressed as fold change units,
were normalized with GAPDH and referred to the untreated cells considered
as calibrator and represent the mean of three experiments (*P< 0.05). (D)
Lysates of SKO-007(J3) cells untreated or treated with JQ1 or lenalidomide
(5 μM) were subjected to Western blotting using anti-IKZF1, anti-IKZF3, and
actin antibodies. The proteins transferred to nitrocellulose membranes were
stained with Ponceau to verify that similar amounts of proteins had been
loaded in each lane. Data are representative of one out of three independent
experiments. (E) Real-time PCR analysis of total mRNA obtained from SKO-
007(J3) cells, untreated or treated with JQ1, lenalidomide, or the combination
of the two drugs as described above for 48 h. Data, expressed as fold change
units, were normalized with GAPDH and referred to the untreated cells
considered as calibrator and represent the mean of 3 experiments (*P< 0.05).
(F) Lysates of SKO-007(J3) cells untreated or treated with JQ1 and/or
lenalidomide (Lena) for 24 or 48 h as described above were subjected to
Western blotting using anti-IRF4 and actin antibodies. The proteins transferred
to nitrocellulose membranes were stained with Ponceau to verify that similar
amounts of proteins had been loaded in each lane. Data are representative
of one out of two independent experiments. Densitometric analysis of
normalized IRF4/actin is shown. (TIF 8785 kb)
Additional file 7: (A, B) Treatment with the indicated concentrations of
JQ1 (48 h) represses IRF4 and upregulates MICA mRNA expression in
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SKO-007(J3) cells. Data of real-time PCR analysis, expressed as fold change
units, were normalized with GAPDH and referred to the untreated cells
considered as calibrator. Data represent the mean of three experiments
(*P < 0.05). (TIF 2956 kb)
Additional file 8: Schematic representation of the PROTAC ARV-825.
(TIF 3981 kb)
Additional file 9: shRNA interference of BRD4 upregulates MICA
expression in SKO-007(J3) cells. (A) MICA, MICB, and PVR/CD155 cell surface
expression were analyzed by flow cytometry on pLKO-control (non-target-
ing) or pLKO-BRD4-lentivirus-infected SKO-007(J3) cells (72 h). The MFI of
MICA, MICB, and PVR/CD155 was calculated based on three independent
experiments and evaluated by paired Student t test (*P < 0.05). (B) A
representative histogram of MICA upregulation is shown. (TIF 2314 kb)
Additional file 10: MICA cell surface expression was analyzed by flow
cytometry on SKO-007(J3) cells treated with OTX015 (0.5 μM) for 72 h. The MFI
of MICA were calculated based on at least four independent experiments and
evaluated by paired Student t test (*P< 0.05). The white-colored histogram
represents basal expression of MICA, while the grey histogram represents the
expression after treatment with the drug. (TIF 2407 kb)
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